Efficacy of Maintenance Therapy with Rituximab or Ofatumumab in CLL


Efficacy of Maintenance Therapy with Rituximab or Ofatumumab in CLL
Slides from presentations at ASH 2014 and transcribed comments from a recent interview with Stephen M Ansell, MD, PhD (1/20/15)
Greil R et al. Rituximab maintenance after chemoimmunotherapy induction in 1st and 2nd line improves progression free survival: Planned interim analysis of the international randomized AGMT-CLL8/a Mabtenance trial. Proc ASH 2014;Abstract 20.

van Oers MHJ et al. Ofatumumab (OFA) maintenance prolongs PFS in relapsed CLL: Prolong study interim analysis results. Proc ASH 2014;Abstract 21.

Dr Ansell is Professor of Medicine in the Division of Hematology at the Mayo Clinic in Rochester, Minnesota.